DEVA "Doktor, Eczacı ve Alatları" (Physicians, Pharmacists and Diagnostics) Sanayi ve Ticaret A.Ş. was incorporated.
The first manufacturing facility is established in Tünel, Beyoğlu
Bomonti pharmaceutical plant was opened.
The ampoule plant was set up.
The production of Tetracycline and Oxytetracycline was realized as the first pharmaceutical raw material in Turkey.
Vetaş Oksitosin , the first oxytocin for veterinary use, and Vetaş Atropin , the first anticholinergic product in the Turkish market, are launched
Carlo Erba pharmaceutical plant was purchased.
With the production of Gentamicine in its active pharmaceutical ingredient manufacturing facilities, it was listed among 5 establishments to produce this active ingredient throughout the world.
The first Gentamycin-containing products are launched in the market: Gentavet Solution for Injection, Gentavet-G Eye and Ear Drops, and Gentavet-D Skin ointment.
The majority ownership of DEVA Holding was transferred to EastPharma Limited, a business venture of GEM Global Equities Management S.A. In connection with this restructuring, Phillip Haas was elected as the new Chairman of the Board of Directors in July 2006.
The company headquarters moved to its new building in Halkalı. Production plant construction was started in çerkezköy and Köseköy İzmit.
R&D center “DEVARGE” was established. SAP (Systems, Applications and Products in Data Processing), the world’s best and most effective reporting system for manufacturing sales and supply channels, is successfully introduced.
DEVA was deemed worthy of the first prize in the “R&D Study of the Year” branch of the Golden Mortar competition.
As of 30.12.2016, it has merged with DEVA Holding A.Ş., the main shareholder in the company. It will continue operating within DEVA Holding A.Ş. with the Vetaş brand. Kartepe Manufacturing Plant received FDA approval.
4 new products (Dectocide Solution for Injection, Spectovet Oral Gel, Betacolin Suspension for Injection and Ricogard Solution for Injection) are launched.
Vetimisin RTU Suspension for Injection and Paromisin Powder for Oral Solution were introduced.